What You Should Know:– AccurKardia, a diagnostics technology innovator, has initiated a multicenter clinical pilot for its AK+ Guard technology. – The AI-powered device, which has been designated as an FDA Breakthrough Device, can detect hyperkalemia—an excess of serum potassium in the blood—using a standard Lead I ECG. The AK+ Guard software is compatible with a wide range of FDA-cleared consumer and clinical wearables, such as smartwatches. This enables remote monitoring of hyperkalemia, which could significantly improve patient outcomes and reduce the burden on the healthcare system. 89% Accuracy in Detecting Moderate to Severe HyperkalemiaIn a retrospective clinical validation study of over 20,000 patients, AK+ Guard achieved an impressive 89% accuracy in detecting moderate-to-severe hyperkalemia, a result on par with many gold-standard diagnostic tools.